Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan.

International journal of cancer - 15 Oct 2010

Scartozzi Mario, Mandolesi Alessandra, Giampieri Riccardo, Pierantoni Chiara, Loupakis Fotios, Zaniboni Alberto, Galizia Eva, Giustini Lucio, Silva Rosa Rita, Bisonni Renato, Berardi Rossana, Biagetti Simona, Menzo Stefano, Falcone Alfredo, Bearzi Italo, Cascinu Stefano

Abstract excerpt

Seventy to 40% of K-RAS wild type colorectal tumors does not seem to benefit from treatment with antiepidermal growth factor receptor (anti-EGFR) monoclonal antibodies. Recent data suggested that in presence of IGF-1 system, altered activation colorectal cancer cells may escape anti-EGFR mediated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Camptothecin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Immunoenzyme Techniques

Share to Insulin-Like Growth Factor I

Share to Irinotecan

Share to ras Proteins

Share to Survival Rate

Source

Identifiers

PMID: 20099280
DOI: 10.1002/ijc.25193

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20099280-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan.PMID 20099280Read ↗

Drugging IGF-1R in cancer: New insights and emerging opportunitiesSemantic proximity Read ↗

Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?Semantic proximity Read ↗

Role of insulin-like growth factor 1 receptor signalling in cancerSemantic proximity Read ↗

Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapySemantic proximity Read ↗

Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancerSemantic proximity Read ↗

Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancer.Semantic proximity Read ↗

The efficacy of IGF-I receptor monoclonal antibody against human gastrointestinal carcinomas is independent of k-ras mutation status.Semantic proximity Read ↗

The IGF-1 receptor and its contributions to metastatic tumor growth—novel approaches to the inhibition of IGF-1R functionSemantic proximity Read ↗

Importance of the type I insulin-like growth factor receptor in HER2, FGFR2 and MET-unamplified gastric cancer with and without Ras pathway activation.Semantic proximity Read ↗

The IGF-I/IGF-I Receptor Pathway: Implications in the Pathophysiology of Thyroid CancerSemantic proximity Read ↗

Differential expression patterns of the insulin-like growth factor 2 gene in human colorectal cancer.Semantic proximity Read ↗

Growth factor receptor interplay and resistance in cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.